Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05714085 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
A Phase 2 study of Heart Failure and Left Ventricular Systolic Dysfunction, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 342
- Enrollment target
- 20
- Study locations
NCT05714085: Recruiting Phase 2 study of Heart Failure and Left Ventricular Systolic Dysfunction, sponsored by Merck Sharp & Dohme.
NCT05714085 is a Phase 2 study of Heart Failure and Left Ventricular Systolic Dysfunction that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 342 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05714085, a Phase 2 study of Heart Failure and Left Ventricular Systolic Dysfunction, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 342 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.
Primary Outcome
The change from baseline to Week 16 of the Base Period in log-transformed NT-proBNP will be reported.
Conditions Studied
Interventions
- DRUG Placebo tablet
- DRUG Vericiguat tablet
- DRUG Vericiguat suspension
- DRUG Placebo suspension
Study Locations (20)
California
- The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 0002) - Los Angeles
- Loma Linda University Health System ( Site 0008) - San Bernardino
New York
- Columbia University Medical Center-Pediatric Cardiology ( Site 0016) - New York
- The Children's Hospital at Montefiore ( Site 0030) - The Bronx
Ohio
- Cincinnati Children's Hospital Medical Center ( Site 0034) - Cincinnati
- Cleveland Clinic-Cleveland Clinic Chidren's ( Site 0022) - Cleveland
Pennsylvania
- Children's Hospital of Philadelphia (CHOP) ( Site 0004) - Philadelphia
- Children's Hospital of Pittsburgh ( Site 0010) - Pittsburgh
Colorado
- Children's Hospital Colorado ( Site 0012) - Aurora
District of Columbia
- Children's National Medical Center ( Site 0020) - Washington D.C.
Florida
- Johns Hopkins All Children's Hospital ( Site 0029) - St. Petersburg
Georgia
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital ( Site 0001) - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 342 participants |
| Start Date | 2023-05-31 |
| Est. Completion | 2032-04-15 |
| Phase | Phase 2 |
What NCT05714085 shows while recruiting
NCT05714085 is an interventional study that assigns participants to a tested intervention. The registered 342 participants enrollment target is mid-sized for trials with a published cap, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (83% lower).
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 4 interventions - of which Placebo tablet is the first listed.
NCT05714085 names 20 study sites across 16 states, led by California, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT05714085 about?
NCT05714085 is a clinical study titled "Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)". This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.
What is the current status of trial NCT05714085?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 342 participants. The study started on 2023-05-31. Estimated completion is 2032-04-15.
What conditions does trial NCT05714085 study?
This clinical trial studies the following conditions: Heart Failure, Left Ventricular Systolic Dysfunction.
What interventions are being tested in trial NCT05714085?
The interventions under investigation include: Placebo tablet (DRUG), Vericiguat tablet (DRUG), Vericiguat suspension (DRUG), Placebo suspension (DRUG).
Who is sponsoring clinical trial NCT05714085?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05714085 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05714085's enrollment target sits among peer trials
342 130th of 397 higher than 268 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
RECRUITING · Phase 2
-
Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial
RECRUITING · Phase 2
-
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · Phase 2
-
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
RECRUITING · Phase 2
-
Metformin for Pulmonary Hypertension HFpEF
RECRUITING · Phase 2
-
The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283850 · 342 participants · Phase 2
Surviving PEA in Roanoke (SPEAR) Study
- NCT06188702 · 342 participants · Phase 1
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
- NCT06544941 · 342 participants · NA
Improving Maternal Sleep and Mental Health
- NCT06852170 · 341 participants · NA
Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI